Cover Image
市場調查報告書

血管再阻塞:開發中產品分析

Restenosis - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 213108
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
血管再阻塞:開發中產品分析 Restenosis - Pipeline Review, H2 2017
出版日期: 2017年08月16日 內容資訊: 英文 48 Pages
簡介

是導致血流受限的血管再度阻塞。症狀包括呼吸急促,步行困難和胸痛。危險因素包括年齡增長,性別,家族史,種族和糖尿病。治療包括手術和溶栓治療。

本報告提供血管再阻塞的治療藥開發情形調查分析,提供開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

血管再阻塞概要

治療藥的開發

  • 開發中產品:概要
  • 開發中的治療藥:各企業
  • 調查中的治療藥:各大學/研究機關
  • 開發中的產品:各企業
  • 調查中的產品:各大學/研究機關

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Chrysalis BioTherapeutics Inc
  • CytoTools AG
  • XBiotech Inc.

藥物簡介

暫停的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9610IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Restenosis - Pipeline Review, H2 2017, provides an overview of the Restenosis (Cardiovascular) pipeline landscape.

Restenosis is re-narrowing of a blood vessel which leads to restricted blood flow. Symptoms include shortness of breath, difficulty walking and chest pain. Risk factors include increasing age, gender, family history or race and diabetes. Treatment includes surgery and thrombolytic therapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Restenosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Restenosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Restenosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Restenosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Preclinical stages are 1 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Restenosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Restenosis (Cardiovascular).
  • The pipeline guide reviews pipeline therapeutics for Restenosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Restenosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Restenosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Restenosis (Cardiovascular)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Restenosis (Cardiovascular).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Restenosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Restenosis - Overview
    • Restenosis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Restenosis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Restenosis - Companies Involved in Therapeutics Development
    • Chrysalis BioTherapeutics Inc
    • CytoTools AG
    • XBiotech Inc
  • Restenosis - Drug Profiles
    • (connective tissue growth factor + insulin human) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMW-02Ak - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HMW-02Ap - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • HO-3867 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • rusalatide acetate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TW-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Xilonix - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Restenosis - Dormant Projects
  • Restenosis - Discontinued Products
  • Restenosis - Product Development Milestones
    • Featured News & Press Releases
      • Jan 03, 2013: XBiotech Receives Fast Track Designation From FDA For True Human Monoclonal Antibody Therapy Targeting Inflammatory Cytokine IL-1a For Restenosis
      • Nov 20, 2012: XBiotech Reports Positive Phase II Interim Analysis Results Of MABp1 In Vascular Disease
      • Aug 18, 2011: XBiotech Announces Initiation Of Restenosis Clinical Trial In All Five US Sites
      • Dec 22, 2010: XBiotech Files IND For CV-18C3 Monoclonal Antibody Therapy To Treat Peripheral Vascular Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Restenosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Restenosis - Pipeline by Chrysalis BioTherapeutics Inc, H2 2017
  • Restenosis - Pipeline by CytoTools AG, H2 2017
  • Restenosis - Pipeline by XBiotech Inc, H2 2017
  • Restenosis - Dormant Projects, H2 2017
  • Restenosis - Dormant Projects, H2 2017 (Contd..1), H2 2017
  • Restenosis - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Restenosis, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top